iiinova — where your digital self keeps evolving

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 29/09/2025

9/29 I start at Mercy in St. Louis! After reflection & emotional debate, we’ve moved to STL. Working at ZSFG/UCSF has been a profound privilege. The community, patients, & colleagues gave me more than I can ever express. Please know how grateful I am to have been part of this extraordinary team.

010

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 09/06/2025

Honored beyond words to receive the 2025 @ucsfmedicine.bsky.social at @zsfgcare.bsky.social Exceptional Physician Award. It is an incredible privilege to work alongside everyone across the SFHN. Thank you!

130

Reposted by Jonathan Davis, MD, MPHS

European Society of Cardiology @escardio.bsky.social · 18/04/2025

NEW! Patients versions of the #Hypertension guidelines Need clear, reliable guidance for your patients with hypertension? The ESC has just released the patient-friendly version of its 2024 ESC Guidelines on management of elevated blood pressure and hypertension.

254

Reposted by Jonathan Davis, MD, MPHS

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 19/12/2024

Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social www.jointcommission.org/resources/aw...

021

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 19/12/2024

021

Reposted by Jonathan Davis, MD, MPHS

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 06/12/2024

Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation. @jaccjournals.bsky.social www.sciencedirect.com/science/arti...

sciencedirect.com

Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction

Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…

076

Reposted by Jonathan Davis, MD, MPHS

Parham Eshtehardi MD @cardioobdoc.bsky.social · 09/12/2024

Management of Iron Deficiency in Heart Failure: Practical Considerations & Implementation of Evidence-Based Iron Supplementation #CardioSky #JACCHF @jaccjournals.bsky.social @robmentz.bsky.social @dranulala.bsky.social @hfsa.bsky.social @accintouch.bsky.social www.jacc.org/doi/10.1016/...

1116

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 06/12/2024

sciencedirect.com

Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction

Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…

076

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 06/12/2024

We are thrilled to be honored with the 2024 California Assoc of Public Hospitals (CAPH)/Safety-net Institute (SNI) Quality Leaders Award for Equity for our work leveraging #AI & machine learning in our #EMR to better identify & care for high risk ppl w #HeartFailure

010

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 04/12/2024

No plans this weekend? Not too late to sign up for the 41st Annual #UCSF #ZSFG Advances in Heart Disease CME! We have a fantastic lineup ready to go! @accintouch.bsky.social @ahascience.bsky.social @hfsa.bsky.social @aspcardio.bsky.social virtualce.ucsf.edu/advances-in-...

virtualce.ucsf.edu

41st Annual Advances in Heart Disease

012

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 23/11/2024

Novel ExCiTe approach aimed at improving trainee recruitment into AHFTC. Great work Edan Zitelny, Rachna Kataria & team @noshreza.bsky.social @cardionerds.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jcardfail.bsky.social @shelleyzieroth.bsky.social onlinejcf.com/article/S107...

0167

Reposted by Jonathan Davis, MD, MPHS

Dr Martha Gulati @drmarthagulati.bsky.social · 16/11/2024

#LBCT #SUMMIT trial #AHA24 💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity 📎 @NEJM www.nejm.org/doi/full/10....

23822

Reposted by Jonathan Davis, MD, MPHS

AHA Science @ahascience.bsky.social · 16/11/2024

BPROAD presented at #AHA24 showed in those w/ type 2 diabetes & elevated systolic blood pressure (SBP), intensive SBP lowering (<120 mmHg) reduced major adverse CV events (MACE) by 21% compared to standard treatment (<140 mmHg). Watch this for one attendee’s take on the data.

099

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 16/11/2024

1st post! The 3 rules of #GDMTWorks for #HFrEF: 1. Start more 2.⬆️doses 3. Keep them going #QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social

1114